SUPPLEMENTAL TABLE E1. Comparison of mean differences between three groups according to eGFR

$eGFR \ge 60mL/min/1.73m^2$	Placebo	Oral 1,000 IU daily	200,000 IU injection	p-value*
	(group A, n = 17)	(group B, n = 14)	(group C, n = 13)	
baPWV (cm/sec)	-41.6 ± 36.9	21.8 ± 37.2	12.7 ± 52.5	0.482
ABI	0.03 ± 0.020	0.02 ± 0.02	-0.01 ± 0.03	0.470
FGF-23 (pg/mL)	0.85 ± 1.55	1.25 ± 1.48	0.40 ± 2.38	0.948
Sclerostin (pg/mL)	27.7 ± 21.1	-1.7 ± 21.2	25.6 ± 31.3	0.599
25(OH)D (ng/mL)	-3.2 ± 1.3	9.1 ± 1.2	11.8 ± 1.9	< 0.001**
Adequacy of 25(OH)D (%)	0	2 (14)	3 (23)	0.130
Parathyroid hormone (pg/mL)	-2.4 ± 2.3	-7.1 ± 2.2	-2.5 ± 3.4	0.286
Hemoglobin A1c (%)	-0.05 ± 0.15	0.09 ± 0.15	0.19 ± 0.22	0.656
Total-cholesterol (mg/dL)	-2.2 ± 11.4	-5.7 ± 10.3	3.6 ± 14.9	0.877
Triglyceride (mg/dL)	55.0 ± 32.0	16.2 ± 30.3	-66.3 ± 48.8	0.145
HDL-cholesterol (mg/dL)	-1.3 ± 1.6	-1.3 ± 1.5	3.3 ± 2.4	0.241
LDL-cholesterol (mg/dL)	-2.2 ± 4.8	10.2 ± 4.4	5.5 ± 7.1	0.206
eGFR (mL/min/1.73m ²)	-2.78 ± 1.85	-0.94 ± 1.80	1.12 ± 2.73	0.516
Calcium (mg/dL)	-0.03 ± 0.10	0.03 ± 0.09	-0.09 ± 0.13	0.712
eGFR < 60 mL/min/1.73m ²	Placebo	Oral 1,000 IU daily	200,000 IU injection	p-value*
	(group A, n = 16)	(group B, $n = 20$)	(group C, n = 12)	
baPWV (cm/sec)	58.9 ± 79.0	57.7 ± 82.8	19.1 ± 148.1	0.973
ABI	0 ± 0.03	0.02 ± 0.03	-0.01 ± 0.06	0.830
FGF-23 (pg/mL)	-1.04 ± 1.41	0.28 ± 1.43	5.26 ± 2.66	0.143
Sclerostin (pg/mL)	-2.3 ± 14.0	2.6 ± 14.0	-2.1 ± 26.3	0.969
25(OH)D (ng/mL)	-0.5 ± 2.3	11.8 ± 2.3	18.4 ± 3.6	< 0.001***
Adequacy of 25(OH)D (%)	1 (6)	5 (25)	7 (58)	0.028
Parathyroid hormone (pg/mL)	-14.6 ± 3.1	-8.6 ± 3.1	-22.7 ± 5.5	0.129

Hemoglobin A1c (%)	0.28 ± 0.16	0.23 ± 0.16	0.50 ± 0.25	0.716
Total-cholesterol (mg/dL)	2.1 ± 7.5	0.1 ± 8.1	-3.2 ± 11.9	0.934
Triglyceride (mg/dL)	28.3 ± 14.1	43.3 ± 15.0	-57.9 ± 26.3	0.019****
HDL-cholesterol (mg/dL)	-2.3 ± 3.0	-1.9 ± 3.1	9.0 ± 5.4	0.229
LDL-cholesterol (mg/dL)	-3.6 ± 5.9	0.6 ± 6.1	-0.4 ± 10.6	0.879
eGFR (mL/min/1.73m ²)	2.66 ± 3.75	-0.81 ± 3.75	11.39 ± 6.04	0.301
Calcium (mg/dL)	0.06 ± 0.10	0.05 ± 0.10	0.35 ± 0.16	0.316

Data are presented as estimated mean \pm standard error (SE); *p value was calculated by ANCOVA with adjustment for age, sex, smoking status, duration of diabetes, history of cardiovascular disease, body mass index and baseline values; **p value of overall mean differences between three groups: p < 0.001 between group A and B, p < 0.001 between group B and C; ***p value of overall mean differences between three groups: p < 0.001 between group A and B, p < 0.001 between group A and C, p = 0.061 between group B and C; ****p value of overall mean differences between three groups: p = 0.4717 between group A and B, p = 0.011 between group A and C, p = 0.006 between group B and C; PWV, pulse wave velocity; ABI, ankle brachial index; FGF-23, fibroblast growth factor-23; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate

https://doi.org/10.1024/0300-9831/a000642